Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Net Cash Flow (2016 - 2025)

Bio-Techne has reported Net Cash Flow over the past 17 years, most recently at $27.5 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $27.5 million for Q4 2025, up 708.09% from a year ago — trailing twelve months through Dec 2025 was -$16.2 million (down 136.03% YoY), and the annual figure for FY2025 was -$1.5 million, up 94.21%.
  • Net Cash Flow for Q4 2025 was $27.5 million at Bio-Techne, up from -$16.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TECH hit a ceiling of $54.4 million in Q2 2023 and a floor of -$46.9 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was $5.6 million (2022), compared with a mean of $650600.0.
  • Biggest five-year swings in Net Cash Flow: tumbled 606.1% in 2023 and later surged 708.09% in 2025.
  • Bio-Techne's Net Cash Flow stood at $12.4 million in 2021, then plummeted by 163.62% to -$7.9 million in 2022, then tumbled by 177.2% to -$22.0 million in 2023, then surged by 79.4% to -$4.5 million in 2024, then surged by 708.09% to $27.5 million in 2025.
  • The last three reported values for Net Cash Flow were $27.5 million (Q4 2025), -$16.0 million (Q3 2025), and $8.2 million (Q2 2025) per Business Quant data.